Maraviroc
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Maraviroc: From HIV-1 Infection to Multiple Endocrine Neoplasia
One-Sentence Summary
Maraviroc is a CCR5 antagonist originally developed to block HIV-1 entry into CD4+ T cells for the treatment of HIV-1 infection. The TxGNN model assigns its highest score to Multiple Endocrine Neoplasia, but this prediction is supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic assessment flags it as a likely false positive.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in Denmark market data; drug is a CCR5 antagonist historically indicated for HIV-1 infection |
| Predicted New Indication | Multiple Endocrine Neoplasia |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L5 (model prediction only, no clinical trials or literature) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Maraviroc is not available from the structured DrugBank field in this pack (marked as a data gap). Based on the repurposing rationale supplied alongside the predictions, Maraviroc acts as a CCR5 antagonist, blocking chemokine receptor CCR5 signalling and thereby preventing HIV entry into CD4+ T cells.
Multiple Endocrine Neoplasia (MEN) is driven by MEN1/RET gene mutations that cause endocrine tumour proliferation — a pathway with no established biological link to CCR5-mediated immune cell chemotaxis. The evidence pack’s own mechanistic assessment explicitly characterizes this as “a candidate with an extremely high prediction score but an implausible mechanism, most likely a false positive” (原文: 屬預測分數極高但機轉不合理的假陽性候選).
In other words, the very high TxGNN score (99.82%) reflects a strong pattern match in the knowledge graph, not a validated pharmacological rationale. No clinical trials, registry entries, or peer-reviewed literature connect Maraviroc to MEN, and the drug’s known immunomodulatory/antiviral mechanism does not translate mechanistically to endocrine tumorigenesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Maraviroc is currently not marketed in Denmark (market status: Not marketed; 0 marketing authorisations on record), so no Danish product/authorisation data is available for this evaluation.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (Multiple Endocrine Neoplasia) has no supporting clinical trials or literature (Evidence Level L5), and the evidence pack’s own mechanistic review identifies it as a likely false positive with no plausible biological link between CCR5 antagonism and MEN1/RET-driven tumorigenesis.
To proceed, the following is needed:
- TFDA/SmPC label warnings and contraindications (currently a blocking data gap — required before any safety pre-assessment)
- Confirmed mechanism-of-action data from DrugBank (currently a data gap affecting mechanistic-link analysis)
- Preclinical or mechanistic studies specifically linking CCR5 signalling to MEN1/RET pathways, if this candidate is to be pursued further
- Independent confirmation that this is not a knowledge-graph artifact, given the pack’s own flag of likely false-positive status
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.